Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Recurrent C. Diff Clear all
Recruiting Phase 3 Interventional

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452
View directory record Official record
Conditions
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
Interventions
VE303, Placebo
Biological
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 4:30 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT03788434
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile, Clostridioides Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile, CDI
Interventions
VE303, Placebo
Drug
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
29
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Canoga Park, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 20, 2026, 4:30 AM EDT
Completed Phase 2 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

NCT02589847
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
RBX2660, Standard of Care Antibiotics
Biological · Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
28
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 20, 2026, 4:30 AM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

NCT05831189
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
RBX2660
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 20, 2026, 4:30 AM EDT
Recruiting Phase 2 Interventional

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

NCT07285213
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
AZD5148, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
43
States / cities
Phoenix, Arizona • Chula Vista, California • Sacramento, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 20, 2026, 4:30 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis

NCT01973465
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Stool
Biological
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 20, 2026, 4:30 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

NCT03497806
View directory record Official record
Conditions
Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI, Recurrent C. Diff, rCDI, C. Difficile, Recurrent CDI, FMT, Fecal Microbiota, Fecal Transplant
Interventions
CP101
Biological
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
53
States / cities
Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 20, 2026, 4:30 AM EDT
Completed Phase 3 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

NCT03931941
View directory record Official record
Conditions
Clostridium Difficile Infection, Infection, Communicable Diseases
Interventions
RBX2660
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
46
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 20, 2026, 4:30 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

NCT03110133
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
Full Spectrum Microbiota, Placebo
Drug
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
54
States / cities
Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 20, 2026, 4:30 AM EDT
Terminated Phase 2 Interventional Results available

FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI

NCT02255305
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
FMT, Antimicrobials
Biological · Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 20, 2026, 4:30 AM EDT
Not listed Phase 1 Interventional

Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection

NCT02134392
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Fecal Microbiota Transplantation
Biological
Lead sponsor
Jonathan Gisser
Other
Eligibility
2 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 20, 2026, 4:30 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

NCT03462459
View directory record Official record
Conditions
Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection, CDI, C.Difficile Diarrhea, C. Diff Colitis, C.Difficile Colitis
Interventions
Vancomycin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 20, 2026, 4:30 AM EDT
Completed Phase 1 Interventional

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

NCT02830542
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
SER-262, Placebo
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Athens, Alabama • Fountain Valley, California • La Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 20, 2026, 4:30 AM EDT
Terminated Phase 4 Interventional Results available

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

NCT04626947
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, C. Diff. Infections
Interventions
Bezlotoxumab
Biological
Lead sponsor
David Binion, MD
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 20, 2026, 4:30 AM EDT
Terminated Phase 4 Interventional

Oral Vancomycin for Preventing Clostridium Difficile Recurrence

NCT03200093
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Oral Vancomycin, Placebo
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 20, 2026, 4:30 AM EDT
Terminated Phase 3 Interventional Results available

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

NCT05153499
View directory record Official record
Conditions
Recurrent C. Difficile Infection
Interventions
CP101, Placebo
Biological · Other
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
61
States / cities
Phoenix, Arizona • Mission Hills, California • Oakland, California + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 20, 2026, 4:30 AM EDT
Recruiting No phase listed Observational

C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.

NCT07250724
View directory record Official record
Conditions
Clostridioides Difficile Infection Recurrence
Interventions
Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment.
Other
Lead sponsor
Bactolife A/S
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Atlanta, Georgia • Royal Oak, Michigan • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 20, 2026, 4:30 AM EDT
Completed Phase 2 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

NCT02299570
View directory record Official record
Conditions
Enterocolitis Clostridium Difficile Recurrent
Interventions
RBX2660 (microbiota suspension), Placebo
Biological · Other
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
19
States / cities
Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 20, 2026, 4:30 AM EDT
Completed Phase 2 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

NCT01925417
View directory record Official record
Conditions
Recurrent Clostridium Difficile Infection
Interventions
RBX2660 (microbiota suspension)
Biological
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 20, 2026, 4:30 AM EDT
Recruiting Not applicable Interventional

Fecal Microbiota Transplantation for C Diff Infection

NCT01905709
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Human fecal matter
Biological
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 20, 2026, 4:30 AM EDT